Alkermes Announces Initiation of Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD.
Business Wire › February 18, 2009
Linked as:
Extract
Alkermes Announces Initiation of Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD.
CAMBRIDGE, Mass. -- Alkermes, Inc. (NASDAQ: ALKS) today announced the initiation of a phase 2a clinical study of ALKS 27 in patients with chronic obstructive pulmonary disease (COPD). The study will assess the efficacy, safety, tolerability and pharmacokinetics of ALKS ...
See the full content of this document
Sponsored links
